{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,9]],"date-time":"2026-06-09T13:19:28Z","timestamp":1781011168204,"version":"3.54.1"},"reference-count":15,"publisher":"MDPI AG","issue":"10","license":[{"start":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T00:00:00Z","timestamp":1760486400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Medicina"],"abstract":"<jats:p>Background and Objectives: Erlotinib, a tyrosine kinase inhibitor (TKI), is an established therapy for patients with metastatic non-small cell lung cancer (NSCLC) harboring epidermal growth factor receptor (EGFR) mutations. Preclinical and clinical evidence suggests that chronic stress, mediated through \u03b2-adrenergic signaling, promotes tumor progression, angiogenesis, and therapy resistance. Furthermore, interactions between \u03b2-adrenergic signaling and EGFR pathways have been hypothesized to negatively influence treatment responses. Based on this rationale, we investigated whether concomitant beta-blocker use may improve survival outcomes in EGFR-mutant NSCLC patients treated with erlotinib. Materials and Methods: This retrospective analysis included 103 patients with metastatic EGFR-mutant NSCLC who received erlotinib. Patients were classified according to concurrent beta-blocker use, defined as continuous therapy for at least six months prior to erlotinib initiation, prescribed for cardiovascular indications. Progression-free survival (PFS) and overall survival (OS) were compared between beta-blocker users and non-users. Results: Patients receiving erlotinib with concomitant beta-blocker therapy achieved a median PFS (mPFS) of 21.4 months (95% CI, 13.1\u201329.7), compared with 9.7 months (95% CI, 6.7\u201312.7) in non-users (p = 0.003). Median OS (mOS) was 32.4 months (95% CI, 14.8\u201350.0) in the beta-blocker group versus 19.9 months (95% CI, 14.8\u201325.0) in the non-beta-blocker group (p = 0.010). Multivariate Cox regression confirmed beta-blocker use as an independent prognostic factor for both PFS (p = 0.004) and OS (p = 0.014). Conclusions: Concomitant beta-blocker use was associated with significantly prolonged survival in patients with EGFR-mutant metastatic NSCLC receiving erlotinib. These findings support the hypothesis that \u03b2-adrenergic inhibition enhances the efficacy of EGFR-targeted therapy. Prospective studies are warranted to validate these results and to further elucidate the underlying biological mechanisms.<\/jats:p>","DOI":"10.3390\/medicina61101843","type":"journal-article","created":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T06:06:32Z","timestamp":1760508392000},"page":"1843","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Prognostic Impact of Concomitant Beta-Blocker Use on Survival in EGFR-Mutant Metastatic Non-Small Cell Lung Cancer Patients Treated with Erlotinib"],"prefix":"10.3390","volume":"61","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4057-3108","authenticated-orcid":false,"given":"O\u011fuzhan","family":"Y\u0131ld\u0131z","sequence":"first","affiliation":[{"name":"Department of Medical Oncology, Necmettin Erbakan University School of Medicine, Konya 42080, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9614-0651","authenticated-orcid":false,"given":"Talat","family":"Aykut","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Necmettin Erbakan University School of Medicine, Konya 42080, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bahattin Engin","family":"Kaya","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Necmettin Erbakan University School of Medicine, Konya 42080, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4252-1029","authenticated-orcid":false,"given":"\u00d6mer","family":"Gen\u00e7","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Necmettin Erbakan University School of Medicine, Konya 42080, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ali Fuat","family":"G\u00fcrb\u00fcz","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Necmettin Erbakan University School of Medicine, Konya 42080, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fatih","family":"Sa\u00e7kan","sequence":"additional","affiliation":[{"name":"Denizli State Hospital, Denizli 20010, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melek Karakurt","family":"Ery\u0131lmaz","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Necmettin Erbakan University School of Medicine, Konya 42080, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3085-7964","authenticated-orcid":false,"given":"Mehmet Zahid","family":"Ko\u00e7ak","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Necmettin Erbakan University School of Medicine, Konya 42080, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4632-9501","authenticated-orcid":false,"given":"Murat","family":"Araz","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Necmettin Erbakan University School of Medicine, Konya 42080, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2335-3354","authenticated-orcid":false,"given":"Mehmet","family":"Arta\u00e7","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Necmettin Erbakan University School of Medicine, Konya 42080, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,10,15]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"2129","DOI":"10.1056\/NEJMoa040938","article-title":"Activating mutations in the epidermal growth factor receptor underlying responsiveness of non\u2013small-cell lung cancer to gefitinib","volume":"350","author":"Lynch","year":"2004","journal-title":"N. Engl. J. Med."},{"key":"ref_2","first-page":"2892","article-title":"EGFR mutation incidence in non-small-cell lung cancer of adenocarcinoma histology: A systematic review and global map by ethnicity (mutMapII)","volume":"5","author":"Midha","year":"2015","journal-title":"Am. J. Cancer Res."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/S1470-2045(11)70393-X","article-title":"Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): A multicentre, open-label, randomised phase 3 trial","volume":"13","author":"Rosell","year":"2012","journal-title":"Lancet Oncol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"583529","DOI":"10.3389\/fonc.2020.583529","article-title":"Effect of \u03b2-blocker in treatment-na\u00efve patients with advanced lung adenocarcinoma receiving first-generation EGFR-TKIs","volume":"10","author":"Chang","year":"2020","journal-title":"Front. Oncol."},{"key":"ref_5","doi-asserted-by":"crossref","unstructured":"Chaudhary, K.R., Yan, S.X., Heilbroner, S.P., Sonett, J.R., Stoopler, M.B., Shu, C., Halmos, B., Wang, T.J.C., Hei, T.K., and Cheng, S.K. (2019). Effects of \u03b2-adrenergic antagonists on chemoradiation therapy for locally advanced non-small cell lung cancer. J. Clin. Med., 8.","DOI":"10.3390\/jcm8050575"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"216","DOI":"10.22543\/7674.62.P216223","article-title":"Beta-blockers in cardiovascular therapy: A review","volume":"6","author":"Diaconu","year":"2019","journal-title":"J. Mind Med. Sci."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.bja.2018.03.024","article-title":"Effect of beta-blockers on cancer recurrence and survival: A meta-analysis of epidemiological and perioperative studies","volume":"121","author":"Yap","year":"2018","journal-title":"Br. J. Anaesth."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1007\/s00228-024-03668-8","article-title":"The effect of concomitant beta-blocker use on survival in patients with metastatic renal cell carcinoma treated with a vascular endothelial growth factor receptor inhibitors in the first line","volume":"80","author":"Korkmaz","year":"2024","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1007\/s00228-023-03464-w","article-title":"Could the concomitant use of beta blockers with bevacizumab improve survival in metastatic colon cancer?","volume":"79","author":"Kocak","year":"2023","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"6109","DOI":"10.7314\/APJCP.2013.14.10.6109","article-title":"Does beta-blocker therapy improve the survival of patients with metastatic non-small cell lung cancer?","volume":"14","author":"Aydiner","year":"2013","journal-title":"Asian Pac. J. Cancer Prev."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"102237","DOI":"10.1016\/j.clgc.2024.102237","article-title":"The impact of concomitant medications on the overall survival of patients treated with systemic therapy for advanced or metastatic renal cell carcinoma: A systematic review and meta-analysis","volume":"22","author":"Tsuboi","year":"2024","journal-title":"Clin. Genitourin. Cancer"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1007\/s10585-025-10347-0","article-title":"Impact of concomitant use of proton pump inhibitors or cardiovascular medication on survival outcomes of patients with metastatic renal cell carcinoma treated with nivolumab","volume":"42","author":"Fiala","year":"2025","journal-title":"Clin. Exp. Metastasis"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"2645","DOI":"10.1200\/JCO.2010.33.4441","article-title":"Beta-blocker use is associated with improved relapse-free survival in patients with triple-negative breast cancer","volume":"29","author":"Lei","year":"2011","journal-title":"J. Clin. Oncol."},{"key":"ref_14","first-page":"779","article-title":"Treatment with \u03b2-blockers and reduced disease progression in patients with thick melanoma","volume":"171","author":"Grazzini","year":"2011","journal-title":"Arch. Intern. Med."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1016\/j.eururo.2013.01.007","article-title":"Association between use of \u03b2-blockers and prostate cancer\u2013specific survival: A cohort study of 3561 prostate cancer patients with high-risk or metastatic disease","volume":"65","author":"Grytli","year":"2014","journal-title":"Eur. Urol."}],"container-title":["Medicina"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1648-9144\/61\/10\/1843\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T06:48:47Z","timestamp":1760510927000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1648-9144\/61\/10\/1843"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,15]]},"references-count":15,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2025,10]]}},"alternative-id":["medicina61101843"],"URL":"https:\/\/doi.org\/10.3390\/medicina61101843","relation":{},"ISSN":["1648-9144"],"issn-type":[{"value":"1648-9144","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,15]]}}}